133
Participants
Start Date
April 2, 2019
Primary Completion Date
June 24, 2020
Study Completion Date
June 24, 2020
V114
15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
Pneumococcal 13-valent Conjugate Vaccine (PCV13)
13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)
Single SC dose of 0.5 mL at Visits 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
Meitetsu Hospital ( Site 2805), Nagoya
Sotobo Children's Clinic ( Site 2807), Isumi
Hidaka Children's Clinic ( Site 2803), Dazaifu
Isesaki Municipal Hospital ( Site 2806), Isesaki
Kawasaki Municipal Hospital ( Site 2802), Kawasaki
Yokosuka Kyosai Hospital ( Site 2804), Yokosuka
Suita Municipal Hospital ( Site 2801), Suita
Kobayashi Pediatric Clinic ( Site 2816), Fujieda
Nishida Kodomo Clinic ( Site 2811), Tama
Fukui Aiiku Hospital ( Site 2809), Fukui
Fukui-ken Saiseikai Hospital ( Site 2813), Fukui
Kubota Children's Clinic ( Site 2815), Osaka
Japanese Red Cross Shizuoka Hospital ( Site 2817), Shizuoka
Hosaka Children's Clinic ( Site 2814), Tokyo
Merck Sharp & Dohme LLC
INDUSTRY